Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease.

Ortega-Rodriguez U, Portillo S, Ashmus RA, Duran JA, Schocker NS, Iniguez E, Montoya AL, Zepeda BG, Olivas JJ, Karimi NH, Alonso-Padilla J, Izquierdo L, Pinazo MJ, de Noya BA, Noya O, Maldonado RA, Torrico F, Gascon J, Michael K, Almeida IC.

Methods Mol Biol. 2019;1955:287-308. doi: 10.1007/978-1-4939-9148-8_22.

2.

Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages.

Coelho PS, Klein A, Talvani A, Coutinho SF, Takeuchi O, Akira S, Silva JS, Canizzaro H, Gazzinelli RT, Teixeira MM.

J Leukoc Biol. 2002 May;71(5):837-44.

PMID:
11994509
3.

Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease.

Schocker NS, Portillo S, Brito CR, Marques AF, Almeida IC, Michael K.

Glycobiology. 2016 Jan;26(1):39-50. doi: 10.1093/glycob/cwv081. Epub 2015 Sep 18.

4.

Induction of IL-12 production in human peripheral monocytes by Trypanosoma cruzi Is mediated by glycosylphosphatidylinositol-anchored mucin-like glycoproteins and potentiated by IFN- γ and CD40-CD40L interactions.

Abel LC, Ferreira LR, Cunha Navarro I, Baron MA, Kalil J, Gazzinelli RT, Rizzo LV, Cunha-Neto E.

Mediators Inflamm. 2014;2014:345659. doi: 10.1155/2014/345659. Epub 2014 Jul 9.

5.

Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway.

Procópio DO, Almeida IC, Torrecilhas AC, Cardoso JE, Teyton L, Travassos LR, Bendelac A, Gazzinelli RT.

J Immunol. 2002 Oct 1;169(7):3926-33.

7.

Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease.

Gazzinelli RT, Galvao LM, Krautz G, Lima PC, Cancado JR, Scharfstein J, Krettli AU.

Am J Trop Med Hyg. 1993 Nov;49(5):625-35.

PMID:
8250103
9.

A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA.

Vaccine. 2014 Jun 12;32(28):3525-32. doi: 10.1016/j.vaccine.2014.04.026. Epub 2014 Apr 30.

10.

Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease.

Brito CR, McKay CS, Azevedo MA, Santos LC, Venuto AP, Nunes DF, D'Ávila DA, Rodrigues da Cunha GM, Almeida IC, Gazzinelli RT, Galvão LM, Chiari E, Sanhueza CA, Finn MG, Marques AF.

ACS Infect Dis. 2016 Dec 9;2(12):917-922. Epub 2016 Oct 4.

PMID:
27696820
11.

Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting.

Izquierdo L, Marques AF, Gállego M, Sanz S, Tebar S, Riera C, Quintó L, Aldasoro E, Almeida IC, Gascon J.

Mem Inst Oswaldo Cruz. 2013 Nov;108(7):928-31. doi: 10.1590/0074-0276130112.

12.
13.

Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages.

Camargo MM, Almeida IC, Pereira ME, Ferguson MA, Travassos LR, Gazzinelli RT.

J Immunol. 1997 Jun 15;158(12):5890-901.

PMID:
9190942
14.

Comprehensive glycoprofiling of the epimastigote and trypomastigote stages of Trypanosoma cruzi.

Alves MJ, Kawahara R, Viner R, Colli W, Mattos EC, Thaysen-Andersen M, Larsen MR, Palmisano G.

J Proteomics. 2017 Jan 16;151:182-192. doi: 10.1016/j.jprot.2016.05.034. Epub 2016 Jun 16.

PMID:
27318177
15.

A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease.

Portillo S, Zepeda BG, Iniguez E, Olivas JJ, Karimi NH, Moreira OC, Marques AF, Michael K, Maldonado RA, Almeida IC.

NPJ Vaccines. 2019 Mar 22;4:13. doi: 10.1038/s41541-019-0107-7. eCollection 2019.

16.

Trypanosoma cruzi surface mucins: host-dependent coat diversity.

Buscaglia CA, Campo VA, Frasch AC, Di Noia JM.

Nat Rev Microbiol. 2006 Mar;4(3):229-36. Review.

PMID:
16489349
17.

Intraspecies variation in Trypanosoma cruzi GPI-mucins: biological activities and differential expression of α-galactosyl residues.

Soares RP, Torrecilhas AC, Assis RR, Rocha MN, Moura e Castro FA, Freitas GF, Murta SM, Santos SL, Marques AF, Almeida IC, Romanha AJ.

Am J Trop Med Hyg. 2012 Jul;87(1):87-96. doi: 10.4269/ajtmh.2012.12-0015.

18.

Cyclic AMP decreases the production of NO and CCL2 by macrophages stimulated with Trypanosoma cruzi GPI-mucins.

Talvani A, Coutinho SF, Barcelos Lda S, Teixeira MM.

Parasitol Res. 2009 Apr;104(5):1141-8. doi: 10.1007/s00436-008-1300-1. Epub 2008 Dec 18.

PMID:
19093132
19.

[Partial purification and use of Trypanosoma cruzi glycosidic fractions for Chagas disease diagnosis].

De Lima Rivero AR, Farías Tamoy MN, Tortolero Leal E, Navarro Aguilera MC, Contreras Alvarez VT.

Acta Cient Venez. 2001;52(4):235-47. Spanish.

PMID:
11915441
20.

Sialic Acid Glycobiology Unveils Trypanosoma cruzi Trypomastigote Membrane Physiology.

Lantos AB, Carlevaro G, Araoz B, Ruiz Diaz P, Camara Mde L, Buscaglia CA, Bossi M, Yu H, Chen X, Bertozzi CR, Mucci J, Campetella O.

PLoS Pathog. 2016 Apr 8;12(4):e1005559. doi: 10.1371/journal.ppat.1005559. eCollection 2016 Apr.

Supplemental Content

Support Center